Affidea Group has acquired Uroviva Group, a urology network based in Switzerland, from German Equity Partners IV, a fund managed by independent German investment company ECM, and Uroviva Group’s founding physicians.
Through this acquisition, Affidea Switzerland almost doubled in size from 17 to 33 centers and from 450 to 700 employees, the company said.
Affidea said this move complements the company's out-of-hospital diagnostic services and breast cancer care pathway, making way for the development of an adjacent prostate cancer pathway. It also opens synergies in pathology, diagnostic imaging, and oncology, the company added.
The Uroviva Group has 16 locations across the cantons of Zurich, Lucerne, Zug, Solothurn, and Aargau, and approximately 250 employees. Service offerings include the Da Vinci Surgical System, high-intensity focused ultrasound (HIFU), and Rezum therapy.
By combining their services, the Uroviva centers and Affidea’s existing network will create a model of integrated care for patient access to diagnostics, personalized treatment plans, and continuous monitoring.
